The ALDH1A1 Knockout AGS Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population derived from the AGS human gastric adenocarcinoma cell line, featuring a targeted disruption of the ALDH1A1 gene. This product provides a loss-of-function model for studying aldehyde dehydrogenase 1 family member A1, an enzyme critically involved in retinoic acid biosynthesis and aldehyde detoxification. The polyclonal format retains a heterogeneous edited pool, enabling robust experimental assessment without the constraints of single-cell clonal selection artifacts. Researchers can utilize these cells to investigate the functional consequences of ALDH1A1 ablation in a disease-relevant gastric cancer context.
The AGS parental cell line originates from a poorly differentiated gastric adenocarcinoma and exhibits an epithelial-like, tumorigenic phenotype. Widely employed as an in vitro model for gastric cancer, AGS cells recapitulate key features of aggressive disease, including rapid proliferation and intrinsic chemoresistance. Their genetic background provides a relevant platform for dissecting oncogenic signaling and cancer stem cell biology, particularly when combined with targeted gene edits such as ALDH1A1 knockout. This model thus offers a pertinent system for evaluating tumorigenic potential and therapeutic vulnerabilities.
ALDH1A1 functions as a homotetrameric enzyme that catalyzes NAD+-dependent oxidation of retinaldehyde to retinoic acid, activating nuclear retinoid receptors (RAR??, RXR??) to regulate gene transcription. This pathway is modulated by upstream regulators such as retinoic acid itself, SOX2, NF-??B, and TCF/LEF effectors of Wnt/??-catenin signaling. The enzyme interacts with cellular retinoic acid-binding protein 2 (CRABP2) and directs retinoic acid to RAR/RXR complexes, which control downstream targets including CYP26A1, a retinoic acid?Cmetabolizing enzyme. Disruption of ALDH1A1 therefore attenuates retinoic acid synthesis, curtails RAR/RXR transcriptional activity, and impairs aldehyde detoxification, with effects on reactive oxygen species balance and stem cell maintenance.
In gastric adenocarcinoma, ALDH1A1 is a well-established cancer stem cell (CSC) marker associated with enhanced tumorigenicity, chemoresistance, and poor patient prognosis. Its knockout in AGS cells reduces the CSC phenotype, manifesting as diminished sphere-forming capacity, impaired self-renewal, and increased sensitivity to chemotherapeutic agents. This cell model thereby enables dissection of the mechanistic links between retinoic acid signaling, CSC biology, and drug resistance in gastric cancer. Furthermore, it provides a tool to explore differentiation-inducing therapies that target the retinoic acid pathway, potentially reversing the undifferentiated, aggressive state characteristic of gastric CSCs.
The ALDH1A1 Knockout AGS Polyclonal Cells are suitable for a broad array of applications. The Aldefluor assay, coupled with flow cytometry, permits quantification of ALDH enzymatic activity and assessment of CSC subpopulations. Gene expression analyses via RT-qPCR and western blotting, in combination with retinoic acid quantification, facilitate the study of pathway output. Functional assays such as cell proliferation, sphere formation, and chemosensitivity testing enable evaluation of tumorigenic traits and drug response. Global transcriptomic profiling by RNA-seq uncovers downstream effects of ALDH1A1 loss. These applications support research into gastric cancer biology, retinoic acid signaling, chemoresistance mechanisms, and CSC-targeted therapeutic strategies. For further information, please contact Ascent Research.
